While most Indian pharma players have been facing multiple headwinds over the last few years, Ipca Laboratories has managed to put up a good performance, thanks to its diversified business model.
The stock has rallied almost 82 per cent from our last buy call given in October 2018. Although there may be limited upsides in the near term, the growth prospects over the long run are still intact, given the company’s diversified business model, strong presence in the high-growth therapies in the domestic market and traction in the institutional anti-malaria business.
Ipca’s ability to grow in non-US markets is a key positive, given that other players focussing on the US market continue to face headwinds in the region, leading to a slowdown in growth and reduced profitability.
At the current price of ₹1,233, the stock trades at about 21 times its estimated FY2020-21 per-share earnings; its large-cap peers Sun Pharma, Lupin, Cipla and Dr Reddys trade at 19-22 times their respective FY2020-21 per-share earnings. Investors with a long-term time horizon can accumulate the stock.
Diversified business model
Denne historien er fra January 20, 2020-utgaven av The Hindu Business Line.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra January 20, 2020-utgaven av The Hindu Business Line.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Covid Presents An Opportunity For India
India must attract investors exiting China post-Covid. Streamlining of project clearances and relaxation in FRBM norms will help
Did Alternative Assets Shield You From Covid-19 Volatility?
The assets closely linked to stock and debt markets could not stave off the losses
How To Put Aircraft To Bed
Preserving grounded planes, to get them up and flying at short notice, is a challenging task. Ashwini Phadnis captures the process
There Can Be No Going Back On WFH
Covid-19 has fast-forwarded the shift to ‘work from home’. However, some face-to-face connect will always be needed
UN, WHO Urged To Ensure ‘Benefit Sharing' Of Covid-Related Data
Biopharma firms should reach vaccines, medicines to poor nations at an affordable price, say civil society bodies
With No Clear Signal From Rlys, States Explore Ways To Bring Back Migrants
Quarantine centres, cross-country buses being arranged even as migrants hop on to boats, trucks and ambulances
Centre Allows All Neighbourhood Shops To Open But With Riders
Final call will be taken by local authorities; shopping complexes that draw fewer ‘outsiders’ are permitted to operate
Covid Impact Relatively Muted In India
Compared to Italy and the US, India’s rate of infection spread has been slow. This can be attributed to the strict measures in place
How Global Trade Will Fare Post-Covid
China isn’t likely to lose its pre-eminent position soon. India, for one, will need to make manufacturing globally competitive
How To Curb Harassment In The Virtual Office
Training and sensitisation are essential. Institute a strict dress code and chat etiquette to ensure professionalism during video calls